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Variants of polyoma virus with differences in oncogenic properties have been 
investigated in several laboratories  (1-4). One pair of variants consists of a virus 
grown in a serum containing medium (S variant) which causes thymic and other 
tumors in almost 100 per cent of CaI-If/Bi mice inoculated at birth, and a virus 
grown in fat-free milk medium (M variant) which causes tumors in approxi- 
nmtely 10 per cent of newborn  CaI-If/Bi mice (3). Other properties  of these 
variants have been extensively documented (5). 
A number of investigators have shown that interferon is produced by tissue 
cultures infected with polyoma virus (6-8),  and a  previous  report from this 
laboratory indicated that mouse embryo cultures infected with the M variant 
produced 4-fold or greater titers of interferon than similar  cultures infected 
with the S variant (9). It was of interest, therefore,  to determine whether the 
same difference in interferon production could be found in in vivo infections of 
newborn mice and whether such differences could be correlated  with the onco- 
genicity of the M and S strains.  One report has shown that hamsters may be 
protected against the oncogenic effect of polyoma virus infection by inoculation 
of exogenous interferon (10). 
This paper presents evidence that the previously observed in vitro differences 
in interferon production are present in vivo in S or M variant infected mice, and 
that the different levels of interferon induced by infection with polyoma virus 
variants are correlated with different degrees of resistance  to in vivo infection 
with a heterologous agent, encephalomyocarditis  virus (EMC). Growth curves 
of the variants in vivo showed that the more oncogenic variant grew to higher 
titers early in the course of infection. Finally, data are presented indicating that 
mice  infected with both M  and  S variants together developed  significantly 
fewer tumors than animals infected with the S variant alone. These findings 
suggested that the difference in oncogenic potential observed between the M and 
S polyoma virus variants may be due to the higher level of interferon induced 
by the M variant. 
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Materials and Methods 
Animals.--CaI-If/Bi mice were obtained from a carefully inbred National Cancer Institute 
colony. 
Virus Strains.--The  S variant of polyoma virus had undergone 10 passages in P388 D1 
cells in 40 per cent human serum and 60 per cent mixture No. 199. The M  variant of polyoma 
virus had had 15 passages in t'388 D1 ceils in 20 per cent autoclaved non-fat milk and 80 per 
cent mixture No. 199. The r and r + mutants (11) of encephaiomyocarditls virus were originally 
obtained from Dr. K. K. Takemoto of the National Institute of Allergy and Infectious Dis- 
eases, Bethesda. All animal inoculations were made subcutaneously with 0.05 cc of the speci- 
fied dilution. 
Extraction Procedures.--In 2- and 5-day-old mice, whole extracts of decapitated animals 
were employed. In 10- and 20-day-old animals pools of kidney, thymus, and spleen were used. 
The whole animals were skinned and the limbs removed. The carcasses of at least 3 animals 
per point or the organ pools of several animals were then minced and the volume of the mince 
measured. A  20 per cent by volume suspension of the mince was placed into a  glass tissue 
grinder and ground until a fine suspension resulted. These crude suspensions were assayed for 
polyoma virus in 10-fold serial dilutions. 
For assay of interferon the 20 per cent suspensions were treated with concentrated HCI un- 
til pH 2 was reached. They were then left for 14 hours at 4°C. The precipitate which had formed 
was removed by low speed centfifugafion and 5 N NaOH was added to the resulting solutions 
until neutral pH was reached. A newly formed precipitate was removed by low speed centrifu- 
gation. At this point the solutions were clear. Solutions were then spun in a  Spinco model L 
preparative ultracentrifuge in a No. 50 head at a maximum force of 150,000 g for 3 hours. The 
resultant solutions were used for interferon assays. 
Polyoma Virus T/ters.--Polyoma virus strains were fitered by limiting dilution in milk- 
adapted test tube cultures of P388 D1 ceils, a stable mouse lymphoma cell line. Titers are re- 
ported as 50 per cent tissue culture infectious doses (TCID~) in log10. End points were read 21 
days after inoculation of 0.25 ml into each of 2 or 3 culture tubes per dilution. 
Titers of lnterferon.--interferon was assayed in ME-29 cells,  a  stable line of mouse fibro- 
blasts obtained in its 102nd passage from Dr. Karl Hal)el of the National Institute of Allergy 
and Infectious Diseases. These were grown and maintained in Eagle's medium No. 2 and 10 
per cent fetal calf serum. The ceils were incubated for 14 hours at 36°C in 30 ml plastic culture 
flasks  with  4  ml  of  the  dilution  to  be  tested,  the  fluids  decanted,  and  the  cultures 
then challenged with 30 to 60 plaque-forming units (p.f.u.) of the r mutant of EMC virus. Mter 
incubation for 90 minutes at 36°C, the monolayers were washed, and an overlay containing 
0.9 per cent Noble agar, 10 per cent bovine serum, and plaque medium 199 was applied. A sec- 
ond agar and medium overlay, containing 1:30,000 neutral red, was made at 24 hours, and 
final plaque counts were read at 48 hours. The results of interferon assays are reported as the 
reciprocal of the highest serial dilution showing approximately 50 per cent plaque reduction as 
compared with appropriate controls. 
RESULTS 
Mixe~ Infection with Polyo~  Virus  Varlan~s.--Results  of infection of new- 
born  C~Hf/Bi mice within  12  hours of their birth  by M  strain polyoma  virus 
alone,  S  strain alone,  and M  and  S  strains  together are summarized  in Fig.  1. 
The results are similar to  those in previously published  reports  (5,  12) in that 
inoculation at  birth  with  103'7 TCIDs0  of  the  S  variant  caused  death  due  to 
thymic epithelial tumors in 100 per cent of the  experimental animals within 102 ROBERT  M. FRIEDMAN  AND  ALAN  S. RABSON  73 
days, while inoculation with the same number of infectious units of the M  vari- 
ant failed to cause any deaths within a 150 day observation period. At 160 days 
all 13 animals in the M  variant-infected group were  sacrificed and autopsied. 
Only 1 of 13 had a thymic tumor; no other tumors were noted. 
When newborn Cg-If/Bi mice were simultaneously infected with both  108.7 
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Fro. 1.  Percentage of survivors following inoculation of newborn mice with polyoma virus 
variants. All survivors at 160 days were sacrificed and autopsied. M or S represent mice inocu- 
lated with 10  s  .v TCID60  of the M or S variants respectively. M +  S represents mice inoculated 
with 10  s'v TCID6o of the M variant and 10  s.7 TCIDs0 of the S variant. S(XS) represents mice 
inoculated with 5 X 10  s'7 TCID~0. 
TCIDs0 of the M variant and 108.7 TCID~0 of the S variant, only 6 of 31 (19 per 
cent) animals died of thymic tumors within the first 102 days. Between 102 and 
150 days, 4 additional animals died, 1 with a thymic tumor and 3 with salivary 
gland tumors. All 21  remaining mice were sacrificed and autopsied when  150 
days old. Of these,  13 had no tumors, 3 had thymic tumors only, 2 had both 
thymic and salivary gland tumors, 2 had salivary gland tumors only, and 1 ani- 
mal had a tumor of the orbit. Therefore, at 150 days 68 per cent of the mice in- 
fected with both strains were still alive, and 42 per cent had no tumors. The 
oncogenic effect of the dual infection was intermediary between the effect of in- 74  ONCOGENIC  EFFECT  OF  POLYOM.A  VIRUS  VARIANTS 
fection with each strain separately. Of the animals which did develop tumors, 
1/~ (6 of 18) did not have thymic tumors. 
That these findings were not due to doubling the infecting dose of virus (since 
the double infection was with a total of 2 X  10  8"7 TCIDs0) is shown by the data 
from infection with 5  X  103"7 TCID60 of the S variant alone. The results, also 
shown in Fig. 1, are similar to those seen when 10  s.~ TCID60 of S alone were em- 
ployed. 
These results suggested that infection with the M  variant resulted in some 
protection against the oncogenic action of simultaneously inoculated S variant. 
TABLE  I 
Effect of Infection with Polyoma Virus Variants on Infection with EMC Virus* 
Animal group 
Controls 
Infected with M vari- 
ant 
Infected with S variant 
Dilution of EMC virus pool used (in logto) 
--2.7  --3.0  --4.0  --5.0  --6.0  --6.5 
NJg~  0/15!i  0/4  0/13  1/17  10/24 
0/17  8/16  4/6  4/4  6/6  13/13 
0/6  4/13  4/6  7/7  7/7  ND 
--7.0  LDio 
7/13  -6.8 
ND  --3.0 
ND  -3.5 
* Infected with S or M  polyoma virus variant on day of birth and with EMC virus when 
5 days old. 
:~ No experiment performed on this group. 
§ Reported as number of survivors/total in group. 
Resistance to Infection with a tteterologus Virus.-- 
Newborn C~If/Bi mice were inoculated subcutaneously with 10  s.~ TCID~0  of either M or S 
polyoma variant, and, when 5 days old, infected subcutaneously with various dilutions of an 
r  + variant of EMC virus. Animals were observed for 13 days and the number of deaths in each 
group recorded. The results are tabulated in Table I where they are compared to those in con- 
trols which had not been infected with one of the polyoma virus variants at birth. 
The LDs0 in the control group by the method of Reed and Muench (13) was 
--6.8. In the group preinfected with the M  variant, it was  --3.0, and in the 
group preinfected with the S variant,  -3.5. These results showed an increase 
in the resistance to EMC virus in mice preinfected with polyoma virus, and 
suggested a difference in the degree of resistance induced by the variants. 
The results of infection with a  10  -~'° dilution of EMC virus are presented in 
detail in Fig. 2. These data indicate a significant difference in the degree of re- 
sistance induced by each of the polyoma variants. In the group of 13 animals 
inoculated at birth with the S variant, all but 1 of 9 deaths occurred by the end 
of the 5th day after infection with EMC virus; in the group of 16 animals inocu- 
lated at birth with the M  variant, however, only 1 of 8 deaths occurred before 
the 6th day after EMC virus infection. At 5 days after EMC infection, there- ROBERT  M.  FRIEDMAN  AND  ALAN  S.  RABSON  75 
fore, the difference between the M and S variant-infected groups was highly sig- 
nificant (p <.01). The induced resistance in the M variant group was transient 
and appeared to wane after the 5th day following infection. 
These results indicated that infection at birth with polyoma virus induced 
resistance  to infection with a  heterologous virus,  EMC. They also indicated 
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FIG. 2.  Percentage of survivors following inoculation of a  l0  -s dilution of an EMC virus 
pool into 5-day-old control mice or mice which had been infected with M or S polyoma virus 
variants at birth. 
that a somewhat greater degree of resistance is induced by infection with the 
M variant than with the S variant. The resistance to infection by a heterologous 
virus suggested  that the differing oncogenicity  of the polyoma virus strains 
might be related to variation in in ~/vo production of interferon. 
In Vi~o Production of Interferon Induced by Polyoma Virus Variants.- 
Extracts of whole mice or organ pools taken from 2-, 5-, 10-, or 20-day-old mice after in- 
fection with 10  aa TCID60 of either the M or the S variant on the day of birth were tested for in- 
terferon activity. The results are plotted in Fig. 3. 
While less than 4 units of interferon was present in all of the pools taken from 
animals infected with the S variant, significant titers were found in some of the ~6  ONCOGENIC  EF~'ECT  OF  POLYOMA  VIRUS  VARIANTS 
pools from M variant-infected animals. A peak titer of 20 units was reached on 
the 5th day after infection with the M variant, a fall to 4 units was noted on the 
10th day, and to less than 4 units on the 20th day. These results agree with the 
previously mentioned in *¢tro studies of interferon production by polyoma virus 
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Fla. 3.  Top, titers of interferon recovered from tissue extracts after infection of newborn 
mice with M or S polyoma x~us variants. Bottom, growth of polyoma virus variants in tissues 
of mice infected at birth. 
variants in tissue  culture in that higher  titers of interferon were induced by 
infection with the less oncogenic M variant (9). 
That the antiviral activity tested was due to interferon was shown by its 
properties.  It was stable to pH 2, destroyed by exposure to 95°C for 5 minutes, 
effective  against  a  heterologous  virus  (EMC),  and  was  not  sedimented 
by 150,000 g for 3 hours (14). 
These findings suggested that the in v/vo differences observed in oncogenicity ROBERT  M.  ~FRIEDMAN  AND  ALAN  S.  RABSON  77 
and in protection against EMC virus infection, and the decrease in tumors noted 
in the mixed infection with M and S variants when compared to infection with 
S alone, might have been due to the at least 10-fold greater interferon produc- 
tion induced at 5 days after infection by the M variant when compared to the 
S variant. It was of interest to compare  the in dvo growth curves of the two 
variants to find out whether a depression in growth of the M variant was corre- 
lated with the production of interferon. 
In Vivo Growth Cur~es of Polyoma Virus Variants.--The  growth curves of the 
M and S polyoina virus variants over the 10 day period following infection on 
the day of birth also appear in Fig. 3. The 5 day tissue suspensions from mice 
inoculated with the S variant titered 106 TCIDs0, the 10 day suspensions, 106"6 
TCIDs0.  These figures generally agreed with those observed in similarly con- 
ducted experiments  (15). In contrast, in mice inoculated with the M variant, 
less than 1 TCIDs0  could be recovered  from tissue  suspensions after 2 days, 
while 5 day suspensions fitered 103 "° TCID60. By the 10th day, however, a titer 
of 10  "'b TCID60 was reached. 
These results showed that the S variant grew to a high titer by 5 days after 
inoculation. At 2 days there was at least a 100-fold difference in titers between 
the variants, while by 5 days there was a 1000-fold difference. At 10 days, how- 
ever, the difference was down to 10-fold. The differences noted varied directly 
with the interferon titers produced,  the greatest difference in virus fiters being 
present after 5 days when the highest fiter of interferon produced by the M 
variant was found. 
DISCUSSION 
The findings presented showed that infection with both M and S variants to- 
gether produced significantly fewer tumors than infection with the S variant 
alone. Infection with the M or S variant was associated  with resistance  to in- 
fection with EMC virus; the M  variant, however,  caused a  transient greater 
degree of resistance,  although growth curves of the variants revealed a  1000- 
fold greater titer of the S variant on the 5th day after infection at birth. By the 
10th day, the titer of the S variant was only 10-fold greater.  Finally, tissue ex- 
tracts from animals infected with the M variant had measurable levels of inter- 
feron, reaching a peak on the 5th day after infection on the day of birth, but no 
interferon could be found in comparable extracts from mice infected with the M 
variant. 
The growth curves of the variants during the first 5 days after infection were 
directly correlated with the number of tumors seen later in each group, the more 
oncogenic S variant at 5 days giving rise to a 1000-fold greater virus titer than 
the less oncogenic M variant. Also, the polyoma virus growth during the first 
5 days after infection on the day of birth was inversely correlated with the level 
of interferon produced by infection with each of the variants respectively. 78  ONCOGENIC EFFECT  OF  POLYOMAVIRUS VARIANTS 
Since  newborn  mice  become  progressively resistant  to  the  oncogenic  effect  of 
polyoma virus over the first few days of life (16), it is possible that the level of inter- 
feron produced by infection with the M  variant was enough to depress that variant's 
growth (or the growth of a simultaneously inoculated dose of the S variant) over the 
first few days after infection. This decrease in M  polyoma virus titer, occurring when 
it did, in turn might cause a  decrease in the number of animals later noted to have 
tumors, possibly because a high enough titer of virus to induce tumors was reached 
in the tissues of M  variant-infected mice only after a degree of immunologic maturity 
had developed (17). 
Findings in previously published reports have provided strong evidence that differ- 
ences in antibody production by mice infected with polyoma virus variants could not 
be an important factor in determining the oncogenic effect of these variants. Anti- 
polyoma virus antibody must be inoculated into newborn hamsters or mice before 
polyoma virus infection in order to protect against tumors induced by the virus. When 
antibody inoculation was delayed for  1 hour, however, no protection was observed, 
even in mice in which daily antibody inoculations were kept up for 17 days after in- 
fection  (18,  19).  Moreover,  active  antipolyoma virus  antibody production  in  the 
newborn mouse has not been demonstrated until 10 days following infection at birth 
(15, 5). This suggests that no antibody at all is present during the period of tumor 
induction by polyoma virus infection in the newborn mouse (17).  Since antibody, in 
order to be effective, must be present at or very close to the time of polyoma virus 
inoculation, and since the onset of production of antipolyoma virus antibody does not 
seem to occur in the newborn mouse until several days after infection, differences in 
antigenicity or in levels of antibody induced by polyoma virus strains could not ac- 
count for  their differing oncogenicity. 
Several findings in this work are similar to those in previously published reports 
suggesting interferon effect in vivo. Hitchcock and Isaacs showed protection of mice 
against intraperitoneal inoculation of Bunyamwera virus by intranasal inoculation of 
an avirulent strain of influenza virus (20). Protection against hemorrhagic encephalo- 
pathy by intravenous inoculation of NWS strain of influenza virus was noted in chick 
embryos  with  established allantoic  infections  by  other  influenza  strains  (21).  In 
neither of these cases was circulating interferon found, but attempts at recovery of 
interferon in in  vivo infections, as in  the  newborn M  variant infected mice in  the 
present report, have been successful in the case of localized vaccinia infection in rab- 
bits (22) and guinea pigs (23), in the lungs of influenza-infected mice (24), and in the 
blood of mice with viremia (25).  In all of these studies, the recovery of the infected 
animals could more reasonably be attributed to interferon than to other factors. In 
the instances in which interferon has not been recovered, and in the case in this report 
of the S variant-infected mice which resisted infection with EMC virus, the resistance 
to a  second infection could have been due to levels of interferon below those which 
are presently capable of being measured (20, 21). The inability to find significant titers 
of interferon does not necessarily exclude interferon as a basis for resistance which is 
imparted by infection with a live virus. 
Law  and  Rabson  (5)  in  experiments somewhat  similar to  those  herein reported 
showed that mice infected at birth with the M  variant resisted the oncogenic effect ROBERT  M.  ~'RIEDMAN  AND  ALAN  S.  RABSON  79 
of inoculation with the S variant 10 days later. They concluded  that the resistance 
noted was probably due to the development of antibody since, following inoculation  of 
the M variant at birth, hemagglutinin-inhibiting antibody was present after 10 days, 
and neutralizing antibody, after 15 days. They also suggested  interferon production 
by the M  variant as a possible  additional mechanism to explain their observations, 
and this is consistent with the finding of interferon on the 10th day after infection  at 
birth with the M  variant. It may be that the early developing  resistance to the S 
variant infection  noted in the present study was due to interferon,  whereas the later 
demonstrated resistance in the report of Law and Rabson was due to antibody. This 
was apparently the case in a double infection  with both pantropic and neurotropic 
strains of Rift Valley Fever virus (26). When mice were systemically infected with 
the neurotropic strain first, a very early protection against the pantropic strain was 
felt to be due to interferon and a later developing resistance,  to antibody. 
An additional point of interest, discovered previously and confirmed by this study, 
is the apparent cessation  of interferon production in animal tissues  despite the per- 
sistence of high titers of an infecting virus. Baron et al. (27) have noted that mice with 
an influenza  virus pneumonia cease making detectable levels of interferon at a  time 
when the virus is still present in the lungs. The significant drop in interferon recovered 
from M  strain-infected mice after the 5th day, despite rising polyoma virus titers, is 
another instance  of  this puzzling observation. A possible  explanation may be that 
cells can make only a certain amount of interferon before they become "exhausted" 
for this function, but several other explanations are not unlikely. 
The production of interferon and sensitivity to its antiviral action may be 
important general phenomena among tumor viruses  since  both DNA  tumor 
viruses, such as polyoma virus (6-9),  and RNA tumor viruses, such as Rous 
sarcoma virus (28, 29), and avian lymphomatosis virus (29) have these proper- 
ties. In mouse polyoma virus infection with relatively low doses of virus, where 
multiplication of the infecting agent to high titers in tissues  is probably im- 
portant to the induction of tumors, production of interferon may be decisive in 
determining the final outcome of the system. 
SUMM~LR¥ 
1.  Infection of newborn  CaHf/Bi  mice with  both  the  highly  oncogenic  S 
variant and the poorly oncogenic M  variant of polyoma virus caused signifi- 
cantly fewer tumors than infection with the S variant alone 
2.  Infection of newborn CffIf/Bi mice at birth with either M  or S variant 
caused resistance to infection with a heterologous agent, encephalomyocarditis 
virus, but the M  variant caused a somewhat greater degree of resistance. 
3.  Extracts of tissues of animals infected at birth with the M  variant had 
measurable levels of interferon, reaching a peak on the 5th day after infection 
with the virus. Extracts of animals infected with the S variant showed no such 
activity. 
4.  The growth curves of the two variants in newborn CffIf/Bi mice showed 80  ONCOGENIC  EFFF.CT  OF  POLYOMA  vn~us  VARIANTS 
that the S variant grew to a  1000-fold greater titer than did the M  variant at 5 
days after infection. Samples tested at 10 days showed a 10-fold difference. 
5.  These findings suggested that the difference between the variants in onco- 
genic potential might have been due to the greater interferon production in- 
duced by infection with the M variant than by infection with the S variant. 
We are grateful for the conscientious  and skillful assistance of Miss Francis Legallais and 
Miss Marilyn Shaw. 
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